Enliven Therapeutics Inc. (ELVN NASDAQ) stock market data APIs
$17.8014
0.98(5.5%)
as of April 23, 2025
Enliven Therapeutics Inc. Financial Data Overview
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a CNS penetrant and irreversible HER2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 driven cancers and solid tumors. The company is headquartered in Boulder, Colorado.
Prev. Close
17.8014
Open
18.7839
High
19.5086
Low
17.7309
52 wk Range
13.3-30.03
Market Cap
871 M
Shares Outstanding
49 004 K
EPS
-0.46
Beta
1.091
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Enliven Therapeutics Inc. data using free add-ons & libraries
Get Enliven Therapeutics Inc. Fundamental Data
Enliven Therapeutics Inc. Fundamental data includes:
- Net Revenue:
- EBITDA: -104 237 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-03-12
- EPS/Forecast: -0.5175
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Enliven Therapeutics Inc. News
New
Enliven Therapeutics' Leukemia Candidate Could Challenge Pfizer, AstraZeneca In Broader Target Market: Analyst
Enliven Therapeutics' Leukemia Candidate Could Challenge Pfizer, AstraZeneca In Broader Target Market: Analyst HC Wainwright initiated coverage on Enliven Therapeutics, Inc. (NASDAQ:ELVN) and noted t...
Enliven Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update
Company on track to deliver initial proof of concept data for ELVN-001 and ELVN-002 in 2024 Strong balance sheet, closing the quarter with $263 million in cash, cash equivalents and marketable securi...
7 A-Rated Biotech Stocks for Your August Buy List
Biotech stocks aren’t for everyone. But if you want to dive into a sector that can potentially give you incredible returns, you’ll want to focus your search on A-rated biotech stocks. Biotech com...
Fairmount Funds Management LLC Acquires New Stake in Kiniksa Pharmaceuticals Ltd
Philadelphia-based investment firm, Fairmount Funds Management LLC, recently made a significant addition to its portfolio. The firm acquired a new stake in Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA), a...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
